Crossmark

68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

Crossref DOI link: https://doi.org/10.1007/s00259-021-05596-6

Published Online: 2021-10-28

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mittlmeier, Lena M.

Todica, Andrei

Gildehaus, Franz-Josef

Unterrainer, Marcus

Beyer, Leonie

Brendel, Matthias

Albert, Nathalie L.

Ledderose, Stephan T.

Vettermann, Franziska J.

Schott, Melanie

Rodler, Severin

Marcon, Julian

Ilhan, Harun

Cyran, Clemens C.

Stief, Christian G.

Staehler, Michael

Bartenstein, Peter
Funding

Funding for this research was provided by:

Ludwig-Maximilians-Universität München
License Information

Text and Data Mining valid from 2021-10-28

Version of Record valid from 2021-10-28
More Information

Article History

Received: 3 August 2021

Accepted: 13 October 2021

First Online: 28 October 2021

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent for PET/CT imaging prior to the examination was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below